For premenopausal breast tumor patients with a BMI ≥ 24, triple-negative and HER2-overexpressing patients had the highest mortality risk, whereas for postmenopausal breast tumor patients with a BMI ≥ 24, Luminal-B (HER2-negative) patients had the highest risk of death. This evidence concerns the gene ERBB2 and breast neoplasm.